CoChat
Sign Up
Cited by 111

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Harnessing the exosome-induced immune response for cancer immunotherapy

Gehrmann, Ulf, Näslund, Tanja I., Hiltbrunner, Stefanie, Larssen, Pia, Gabrielsson, Susanne·2014·Seminars in Cancer Biology
DOI 10.1016/j.semcancer.2014.05.003
Open this paper in CoChat — free account

Abstract

In recent years exosomes have emerged as potent stimulators of immune responses and as agents for cancer therapy. Exosomes can carry a broad variety of immunostimulatory molecules depending on the cell of origin and in vitro culture conditions. Dendritic cell-derived exosomes (dexosomes) have been shown to carry NK cell activating ligands and can be loaded with antigen to activate invariant NKT cells and to induce antigen-specific T and B cell responses. Dexosomes have been investigated as therapeutic agents against cancer in two phase I clinical trials, with a phase II clinical trial currently ongoing. Dexosomes were well tolerated but therapeutic success and immune activation were limited. Several reports suggest that multiple factors need to be considered in order to improve exosomal immunogenicity for cancer immunotherapy. These include antigen-loading strategies, exosome composition and exosomal trafficking in vivo. Hence, a better understanding of how to engineer and deliver exosomes to specific cells is crucial to generate strong immune responses and to improve the immunotherapeutic potential of exosomes.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2014.05.003

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Research works printed but not linked: 95

  1. Poschke, 2011, Camouflage and sabotage: tumor escape from the immune system, Cancer Immunol Immunother, 60, 1161, 10.1007/s00262-011-1012-8 · DOI
  2. Zitvogel, 2008, The anticancer immune response: indispensable for therapeutic success?, J Clin Invest, 118, 1991, 10.1172/JCI35180 · DOI
  3. Pulendran, 2011, Immunological mechanisms of vaccination, Nat Immunol, 12, 509, 10.1038/ni.2039 · DOI
  4. Hubert, 2011, Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy, Cancer Res, 71, 5134, 10.1158/0008-5472.CAN-10-4222 · DOI
  5. Semmling, 2010, Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs, Nat Immunol, 11, 313, 10.1038/ni.1848 · DOI
  6. Colino, 2006, Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen, J Immunol, 177, 3757, 10.4049/jimmunol.177.6.3757 · DOI
  7. Viaud, 2009, Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha, PLoS ONE, 4, e4942, 10.1371/journal.pone.0004942 · DOI
  8. Zitvogel, 1998, Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes, Nat Med, 4, 594, 10.1038/nm0598-594 · DOI
  9. Escudier, 2005, Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial, J Transl Med, 3, 10, 10.1186/1479-5876-3-10 · DOI
  10. Morse, 2005, A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer, J Transl Med, 3, 9, 10.1186/1479-5876-3-9 · DOI
  11. Viaud, 2011, Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma, J Immunother, 34, 65, 10.1097/CJI.0b013e3181fe535b · DOI
  12. Buschow, 2010, MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis, Immunol Cell Biol, 88, 851, 10.1038/icb.2010.64 · DOI
  13. Clayton, 2005, Induction of heat shock proteins in B-cell exosomes, J Cell Sci, 118, 3631, 10.1242/jcs.02494 · DOI
  14. Escola, 1998, Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes, J Biol Chem, 273, 20121, 10.1074/jbc.273.32.20121 · DOI · Paper page
  15. Rialland, 2006, BCR-bound antigen is targeted to exosomes in human follicular lymphoma B-cells, Biol Cell, 98, 491, 10.1042/BC20060027 · DOI
  16. Wubbolts, 2003, Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation, J Biol Chem, 278, 10963, 10.1074/jbc.M207550200 · DOI
  17. Saunderson, 2014, CD169 mediates the capture of exosomes in spleen and lymph node, Blood, 123, 208, 10.1182/blood-2013-03-489732 · DOI
  18. Papp, 2008, B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity, Mol Immunol, 45, 2343, 10.1016/j.molimm.2007.11.021 · DOI
  19. McLellan, 2009, Exosome release by primary B cells, Crit Rev Immunol, 29, 203, 10.1615/CritRevImmunol.v29.i3.20 · DOI
  20. Arita, 2008, B cell activation regulates exosomal HLA production, Eur J Immunol, 38, 1423, 10.1002/eji.200737694 · DOI
  21. Saunderson, 2008, Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor, J Immunol, 180, 8146, 10.4049/jimmunol.180.12.8146 · DOI
  22. Muntasell, 2007, T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes, EMBO J, 26, 4263, 10.1038/sj.emboj.7601842 · DOI
  23. Vallhov, 2011, Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro, J Immunol, 186, 73, 10.4049/jimmunol.1001145 · DOI
  24. Clayton, 2004, Adhesion and signaling by B cell-derived exosomes: the role of integrins, FASEB J, 18, 977, 10.1096/fj.03-1094fje · DOI
  25. Pegtel, 2010, Functional delivery of viral miRNAs via exosomes, Proc Natl Acad Sci U S A, 107, 6328, 10.1073/pnas.0914843107 · DOI
  26. Segura, 2005, ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming, Blood, 106, 216, 10.1182/blood-2005-01-0220 · DOI
  27. Nolte-’t Hoen, 2013, Dynamics of dendritic cell-derived vesicles: high-resolution flow cytometric analysis of extracellular vesicle quantity and quality, J Leukocyte Biol, 93, 395, 10.1189/jlb.0911480 · DOI
  28. Segura, 2007, CD8+ dendritic cells use LFA-1 to capture MHC-peptide complexes from exosomes in vivo, J Immunol, 179, 1489, 10.4049/jimmunol.179.3.1489 · DOI
  29. Thery, 1999, Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73, J Cell Biol, 147, 599, 10.1083/jcb.147.3.599 · DOI
  30. Veron, 2005, Accumulation of MFG-E8/lactadherin on exosomes from immature dendritic cells, Blood Cells Mol Dis, 35, 81, 10.1016/j.bcmd.2005.05.001 · DOI
  31. Kim, 2007, Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4, J Immunol, 179, 2242, 10.4049/jimmunol.179.4.2242 · DOI
  32. Thery, 2001, Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles, J Immunol, 166, 7309, 10.4049/jimmunol.166.12.7309 · DOI
  33. Johansson, 2008, Different types of in vitro generated human monocyte-derived dendritic cells release exosomes with distinct phenotypes, Immunology, 123, 491, 10.1111/j.1365-2567.2007.02714.x · DOI
  34. Kim, 2005, Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis, J Immunol, 174, 6440, 10.4049/jimmunol.174.10.6440 · DOI
  35. Bhatnagar, 2007, Exosomes released from infected macrophages contain Mycobacterium avium glycopeptidolipids and are proinflammatory, J Biol Chem, 282, 25779, 10.1074/jbc.M702277200 · DOI
  36. Nguyen, 2003, Evidence that HIV budding in primary macrophages occurs through the exosome release pathway, J Biol Chem, 278, 52347, 10.1074/jbc.M309009200 · DOI
  37. Qu, 2009, P2X7 receptor-stimulated secretion of MHC class II-containing exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1, J Immunol, 182, 5052, 10.4049/jimmunol.0802968 · DOI
  38. Pelchen-Matthews, 2003, Infectious HIV-1 assembles in late endosomes in primary macrophages, J Cell Biol, 162, 443, 10.1083/jcb.200304008 · DOI
  39. Kramer, 2005, HIV interaction with endosomes in macrophages and dendritic cells, Blood Cells Mol Dis, 35, 136, 10.1016/j.bcmd.2005.06.006 · DOI
  40. Deneka, 2007, In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53, J Cell Biol, 177, 329, 10.1083/jcb.200609050 · DOI
  41. Bhatnagar, 2007, Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo, Blood, 110, 3234, 10.1182/blood-2007-03-079152 · DOI
  42. Giri, 2008, Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo, PLoS ONE, 3, e2461, 10.1371/journal.pone.0002461 · DOI
  43. Giri, 2010, Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis-infected and culture filtrate protein-treated macrophages, Proteomics, 10, 3190, 10.1002/pmic.200900840 · DOI
  44. Singh, 2011, Exosomes released from M. tuberculosis infected cells can suppress IFN-gamma mediated activation of naive macrophages, PLoS ONE, 6, e18564, 10.1371/journal.pone.0018564 · DOI
  45. Anand, 2010, Exosomal Hsp70 induces a pro-inflammatory response to foreign particles including mycobacteria, PLoS ONE, 5, e10136, 10.1371/journal.pone.0010136 · DOI
  46. Ramachandra, 2010, Mycobacterium tuberculosis synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation, Infect Immun, 78, 5116, 10.1128/IAI.01089-09 · DOI
  47. Quah, 2007, Mycoplasma contaminants present in exosome preparations induce polyclonal B cell responses, J Leukocyte Biol, 82, 1070, 10.1189/jlb.0507277 · DOI
  48. Mor-Vaknin, 2006, The DEK nuclear autoantigen is a secreted chemotactic factor, Mol Cell Biol, 26, 9484, 10.1128/MCB.01030-06 · DOI
  49. Hsu, 2003, Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides, J Immunother, 26, 440, 10.1097/00002371-200309000-00007 · DOI
  50. Qazi, 2009, Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism, Blood, 113, 2673, 10.1182/blood-2008-04-153536 · DOI
  51. Thery, 2002, Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes, Nat Immunol, 3, 1156, 10.1038/ni854 · DOI
  52. Segura, 2005, Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses, Blood Cells Mol Dis, 35, 89, 10.1016/j.bcmd.2005.05.003 · DOI
  53. Naslund, 2013, Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity, J Immunol, 190, 2712, 10.4049/jimmunol.1203082 · DOI
  54. Gehrmann, 2013, Synergistic induction of adaptive antitumor immunity by codelivery of antigen with alpha-galactosylceramide on exosomes, Cancer Res, 73, 3865, 10.1158/0008-5472.CAN-12-3918 · DOI
  55. Prado, 2008, Exosomes from bronchoalveolar fluid of tolerized mice prevent allergic reaction, J Immunol, 181, 1519, 10.4049/jimmunol.181.2.1519 · DOI
  56. Aline, 2004, Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection, Infect Immun, 72, 4127, 10.1128/IAI.72.7.4127-4137.2004 · DOI
  57. Beauvillain, 2007, A vaccine based on exosomes secreted by a dendritic cell line confers protection against T. gondii infection in syngeneic and allogeneic mice, Microbes Infect, 9, 1614, 10.1016/j.micinf.2007.07.002 · DOI
  58. Morelli, 2004, Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells, Blood, 104, 3257, 10.1182/blood-2004-03-0824 · DOI
  59. Montecalvo, 2008, Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition, J Immunol, 180, 3081, 10.4049/jimmunol.180.5.3081 · DOI
  60. Zhu, 2012, Exosomes as extrapulmonary signaling conveyors for nanoparticle-induced systemic immune activation, Small, 8, 404, 10.1002/smll.201101708 · DOI
  61. Kim, 2006, Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive, Mol Ther, 13, 289, 10.1016/j.ymthe.2005.09.015 · DOI
  62. Manolova, 2008, Nanoparticles target distinct dendritic cell populations according to their size, Eur J Immunol, 38, 1404, 10.1002/eji.200737984 · DOI
  63. Bachmann, 2010, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat Rev Immunol, 10, 787, 10.1038/nri2868 · DOI
  64. Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat Biotechnol, 29, 341, 10.1038/nbt.1807 · DOI · Paper page
  65. Idoyaga, 2011, Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A, Proc Natl Acad Sci U S A, 108, 2384, 10.1073/pnas.1019547108 · DOI
  66. Ding, 2008, Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1, Blood, 112, 2817, 10.1182/blood-2008-05-157396 · DOI
  67. Bryniarski, 2013, Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity, J Allergy Clin Immunol, 132, 170, 10.1016/j.jaci.2013.04.048 · DOI
  68. Bonifaz, 2004, In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination, J Exp Med, 199, 815, 10.1084/jem.20032220 · DOI
  69. Ruiss, 2011, EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells – a new option for the treatment of B-CLL, PLoS ONE, 6, e25294, 10.1371/journal.pone.0025294 · DOI
  70. Esser, 2010, Exosomes from human macrophages and dendritic cells contain enzymes for leukotriene biosynthesis and promote granulocyte migration, J Allergy Clin Immunol, 126, 1032, 10.1016/j.jaci.2010.06.039 · DOI
  71. Subra, 2010, Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins, J Lipid Res, 51, 2105, 10.1194/jlr.M003657 · DOI
  72. Sala, 2010, Transcellular biosynthesis of eicosanoids, Pharmacol Rep, 62, 503, 10.1016/S1734-1140(10)70306-6 · DOI
  73. Torregrosa Paredes, 2012, Bronchoalveolar lavage fluid exosomes contribute to cytokine and leukotriene production in allergic asthma, Allergy, 67, 911, 10.1111/j.1398-9995.2012.02835.x · DOI
  74. Andre, 2004, Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells, J Immunol, 172, 2126, 10.4049/jimmunol.172.4.2126 · DOI · Paper page
  75. Singh, 2012, Exosomes isolated from mycobacteria-infected mice or cultured macrophages can recruit and activate immune cells in vitro and in vivo, J Immunol, 189, 777, 10.4049/jimmunol.1103638 · DOI
  76. Simhadri, 2008, Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function, PLoS ONE, 3, e3377, 10.1371/journal.pone.0003377 · DOI
  77. Reiners, 2013, Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity, Blood, 121, 3658, 10.1182/blood-2013-01-476606 · DOI
  78. Hedlund, 2011, Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells, PLoS ONE, 6, e16899, 10.1371/journal.pone.0016899 · DOI
  79. Hedlund, 2009, Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function, J Immunol, 183, 340, 10.4049/jimmunol.0803477 · DOI
  80. Mincheva-Nilsson, 2006, Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival, J Immunol, 176, 3585, 10.4049/jimmunol.176.6.3585 · DOI
  81. Lamparski, 2002, Production and characterization of clinical grade exosomes derived from dendritic cells, J Immunol Methods, 270, 211, 10.1016/S0022-1759(02)00330-7 · DOI
  82. Coppieters, 2009, No significant CTL cross-priming by dendritic cell-derived exosomes during murine lymphocytic choriomeningitis virus infection, J Immunol, 182, 2213, 10.4049/jimmunol.0802578 · DOI
  83. Hao, 2006, Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes, Cell Mol Immunol, 3, 205
  84. Hao, 2007, Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity, Immunology, 120, 90, 10.1111/j.1365-2567.2006.02483.x · DOI
  85. Chaput, 2004, Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection, J Immunol, 172, 2137, 10.4049/jimmunol.172.4.2137 · DOI
  86. Admyre, 2007, B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines, J Allergy Clin Immunol, 120, 1418, 10.1016/j.jaci.2007.06.040 · DOI
  87. Peche, 2003, Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection, Transplantation, 76, 1503, 10.1097/01.TP.0000092494.75313.38 · DOI
  88. Prado, 2010, Bystander suppression to unrelated allergen sensitization through intranasal administration of tolerogenic exosomes in mouse, Mol Immunol, 47, 2148, 10.1016/j.molimm.2010.04.014 · DOI
  89. Hugues, 2007, Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses, Nat Immunol, 8, 921, 10.1038/ni1495 · DOI
  90. Hivroz, 2012, Crosstalk between T lymphocytes and dendritic cells, Crit Rev Immunol, 32, 139, 10.1615/CritRevImmunol.v32.i2.30 · DOI
  91. Ridge, 1998, A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell, Nature, 393, 474, 10.1038/30989 · DOI
  92. Cinamon, 2008, Follicular shuttling of marginal zone B cells facilitates antigen transport, Nat Immunol, 9, 54, 10.1038/ni1542 · DOI
  93. Blanc, 2007, Reticulocyte-secreted exosomes bind natural IgM antibodies: involvement of a ROS-activatable endosomal phospholipase iPLA2, Blood, 110, 3407, 10.1182/blood-2007-04-085845 · DOI
  94. Link, 2012, Innate immunity mediates follicular transport of particulate but not soluble protein antigen, J Immunol, 188, 3724, 10.4049/jimmunol.1103312 · DOI
  95. Denzer, 2000, Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface, J Immunol, 165, 1259, 10.4049/jimmunol.165.3.1259 · DOI

Cited by

Sorted by citations

See all 111

Metadata

Authors
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2014-10
Volume
28
Pages
58-67
ISSN
1044-579X
DOI
10.1016/j.semcancer.2014.05.003
Cited by
111
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Swedish Research Council
  • Swedish Cancer Foundation
  • Center for Allergy Research Karolinska Institutet
  • Hesselman Foundation
  • David and Astrid Hagelén's Foundation
  • IMTAC (Immune Modulatory Therapies in Autoimmunity and Cancer) Consortium at Karolinska Institutet
  • Cancer Research Foundations of Radiumhemmet
  • Swedish Heart and Lung Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Harnessing the exosome-induced immune response for cancer immunotherapy. https://app.cochat.ai/papers/10.1016/j.semcancer.2014.05.003
The paper
Gehrmann, U., Näslund, T. I., Hiltbrunner, S., Larssen, P., & Gabrielsson, S. (2014). Harnessing the exosome-induced immune response for cancer immunotherapy. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2014.05.003